Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

Serena Williams says she has lost weight using GLP-1 medication. The drugs help manage blood sugar and promote weight loss, ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed ...

Two statistical approaches were used to evaluate the efficacy of four doses of GIP/GLP-1 RA (1 mg, 5 mg, 10 mg, 15 mg) compared to placebo and dulaglutide 1.5 mg in people with type 2 diabetes.

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Carmot’s dual GLP-1/GIP receptor modulator has entered Phase 2 development and has the potential to be best in a new class of treatments for type 2 diabetes and related indications.

Recent research has explored the possibility of repurposing existing medications, typically used for other conditions, to address the challenges of SUD treatment. One such promising group of ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as much a part of the medication infrastructure as statins or thyroid pills.

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with obstructive sleep apnea and type 2 diabetes, according to data ...